| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Interleukin 17 receptor A |
| Clinical data | |
| Trade names | Siliq, Kyntheum, Lumicef |
| Other names | KHK4827, AMG 827 |
| License data | |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| Chemical and physical data | |
| Formula | C6372H9840N1712O1988S52 |
| Molar mass | 143905.93 g·mol−1 |
 N Y (what is this?) (verify) | |
Brodalumab, sold under the brand nameSiliq in the US andKyntheum in the EU, is a humanmonoclonal antibody designed for the treatment of inflammatory diseases.[3][4][5]
In February 2017, it received USFDA approval to treat moderate to severeplaque psoriasis in people who have not improved with other treatments.[6]
Brodalumab binds to theinterleukin-17 receptor and so preventsinterleukin 17 (IL-17) from activating the receptor. This mechanism is similar to that of another anti-psoriasis antibody,ixekizumab, which however binds to IL-17 itself.
Brodalumab was developed byAmgen, Inc. as AMG 827.
In 2013, it was in two phase III clinical trials for the treatment of moderate to severe psoriasis.[7][8]
In November 2014, Amgen andAstraZeneca reported encouraging results for the compound. The companies stated that the compound met theprimary endpoint showing superior skin clearance in a Phase III trial when compared toustekinumab and a placebo.[9]
However, in May 2015, Amgen announced that it was ending its participation in co-development of the compound because of reports of patients having "events of suicidal ideation and behavior".[10] AstraZeneca will be solely responsible for any future development and marketing of brodalumab in all territories except for certain Asian territories such as Japan, whereKyowa Hakko Kirin has rights to brodalumab and continued as KHK4827.
In September 2015, AstraZeneca announced a partnership withValeant Pharmaceuticals in which Valeant took over exclusive rights to develop and commercialize brodalumab.[11] In July 2016, the rights to commercialize brodalumab in Europe were sold toLEO Pharma.[12]
In January 2016, abiologics license application (BLA) was submitted to the US FDA.[13] Approval followed in February 2017.[6]
 | Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byexpanding it. |
 | Thismonoclonal antibody–related article is astub. You can help Wikipedia byexpanding it. |
